Table 2.

Diagnostic accuracy of plasma biomarkers to discriminate non pathological CSF (A−/T−/N−) profiles in the cohort of Montpellier and Barcelona

Non-pathological CSF (A−/T−/N−)	The Montpellier cohort				The Barcelona cohort
Blood biomarkers	AUC	SE	95% CI	p	AUC	SE	95% CI	p
Aβ1–40(Q3)	0.661	0.069	0.530–0.777	0.020	0.638	0.080	0.490–0.769	0.085
Aβ1–40(Q4)	0.672	0.068	0.542–0.785	0.011	–	–	–	–
Aβ1–40(IP-MS)	0.526	0.074	0.396–0.653	0.728	0.549	0.051	0.463–0.633	0.329
Aβ1–42(Q3)	0.548	0.077	0.417–0.675	0.534	0.715	0.076	0.571–0.834	0.044
Aβ1–42(Q4)	0.542	0.076	0.410–0.669	0.601	–	–	–	–
Aβ1–42(IP-MS)	0.638	0.073	0.507–0.755	0.060	0.656	0.048	0.571–0.733	0.001
Tau	0.612	0.078	0.480–0.733	0.149	0.618	0.081	0.470–0.752	0.495
p-tau(181)	0.865	0.049	0.756––0.938	< 0.0001	0.773	0.039	0.697–0.837	< 0.0001
Aβ1–42/Aβ40(Q3)	0.709	0.068	0.580–0.818	0.002	0.848	0.062	0.719–0.934	< 0.0001
Aβ1–42/Aβ40(Q4)	0.753	0.065	0.627–0.854	< 0.0001	–	–	–	–
Aβ1–42/Aβ40(IP-MS)	0.715	0.066	0.587–0.822	0.001	0.661	0.048	0.577–0.739	0.0008
Logistic regression Aβ1–40, Aβ1–42, p-tau(181)	0.904	0.040	0.804–0.964	< 0.0001	0.882	0.050	0.759–0.956	< 0.0001

Biomarkers were quantified using either Quanterix technology (Q3 and Q4) or Shimadzu approach (IP-MS). Significant differences are indicated by bolded p (threshold 0.05)